key: cord-0853338-qr4gl9jb
authors: Cereda, Emanuele; Bogliolo, Laura; Klersy, Catherine; Lobascio, Federica; Masi, Sara; Crotti, Silvia; De Stefano, Ludovico; Bruno, Raffaele; Corsico, Angelo Guido; Di Sabatino, Antonio; Perlini, Stefano; Montecucco, Carlomaurizio; Caccialanza, Riccardo; Belliato, Mirko; Ludovisi, Serena; Mariani, Francesca; Ferrari, Alessandra; Musella, Valeria; Muggia, Chiara; Croce, Gabriele; Barteselli, Chiara; Mambella, Jacopo; Di Terlizzi, Francesco
title: Vitamin D 25OH deficiency in COVID-19 patients admitted to a tertiary referral hospital
date: 2020-11-02
journal: Clin Nutr
DOI: 10.1016/j.clnu.2020.10.055
sha: 64fe9b5c2063c80e67e3406c1fd079e85e2ba815
doc_id: 853338
cord_uid: qr4gl9jb

Background & Aims Great interest has been raised by the possible protective role of vitamin D in coronavirus disease 2019 (COVID-19), but objective data on 25(OH)vitamin D deficiency in hospitalized COVID-19 patients are not conclusive. The aim of this study was to determine the prevalence of 25(OH)vitamin D deficiency in COVID-19 patients admitted to an Italian referral hospital and explore its association with clinical outcomes and the markers of disease severity. Methods In this single-center cohort study, 129 consecutive adult COVID-19 patients hospitalized in an Italian referral center were enrolled from March to April 2020. 25(OH)Vitamin D serum levels were assessed 48 hours since hospital admission and categorized into: normal (≥30 ng/mL), insufficient (<30 - ≥20 ng/mL), moderately deficient (<20 - ≥10 ng/mL), severely deficient (<10 ng/mL). Results The prevalence of 25(OH)vitamin D insufficiency, moderate deficiency and severe deficiency was 13.2%, 22.5% and 54.3%, respectively. 25(OH)Vitamin D deficiency (<20 ng/mL) was not associated with COVID-19 clinical features and outcomes. Unexpectedly, after adjusting for major confounders, a significant positive association between increasing 25(OH)vitamin D levels and in-hospital mortality (on a continuous logarithmic scale, odds ratio=1.73 [95% CI, 1.11 to 2.69]; P=.016) was observed. Conclusions Very low 25(OH)vitamin D levels were highly prevalent and suggestive of deficiency among our hospitalized severe COVID-19 patients, but low 25(OH)vitamin D levels were not associated with outcome variables. Whether 25(OH)vitamin D adequacy may influence clinical outcomes in COVID-19 and the unexpected correlation between higher 25(OH)vitamin D levels and mortality require further investigations by large intervention trials.

25(OH)Vitamin D deficiency (<20 ng/mL) was not associated with COVID-19 clinical features 48 and outcomes. Unexpectedly, after adjusting for major confounders, a significant positive 49 association between increasing 25(OH)vitamin D levels and in-hospital mortality (on a continuous 50 logarithmic scale, odds ratio=1.73 [95% CI, 1.11 to 2.69]; P=.016) was observed.

Introduction 59 If effective vaccines will not be developed and deployed in the next 6 months, wintertime outbreaks 60 of Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) will probably occur, with 61 hundreds of thousands of coronavirus disease 2019 (COVID-19) patients putting again the health 62 care systems under stress, considering that herd immunity has not been reached even in countries 63 heavily hit by the virus. Hence, preventing strategies to mitigate the severity of future possible 64 outbreaks should be identified without delay. In the context of COVID-19, great interest has been 65 raised by the possible protective role of 25(OH)vitamin D, due to its known properties in 66 modulating the endothelial function and the immune response against viral infections, and 67 inhibiting the Renin-Angiotensin-Aldosterone System (RAAS) cascade [1, 2] . 25(OH)Vitamin D 68 plays also a protective role in acute lung injuries, down-regulating renin, Angiotensin Converting 69 Enzyme (ACE) and angiotensin (Ang) genes, up-regulating ACE2 expression and correcting tissue 70 sensitivity to Ang II similarly to ACE inhibitors [1] . In line with this hypothesis, epidemiological 71 data appear to support the concept that the gradient of COVID-19 severity across different countries 72 could be related to the inherent rate of 25(OH)vitamin D deficiency [1] 

One hundred twenty-nine patients (54.3% males, mean age 73.6 ± 13.9 years) were enrolled and 34 105 (26.4%) died during the hospital stay. The prevalence of 25(OH)vitamin D insufficiency, 106 deficiency and severe deficiency was 13.2%, 22.5% and 54.3%, respectively. 25(OH)Vitamin D deficiency (<20 ng/mL) was not associated with COVID-19 clinical features 108 and outcomes (Table 1) . Unexpectedly, after adjusting for major confounders (age, sex, C-reactive 109 protein, ischemic heart disease and severe pneumonia), a significant positive association between 110 increasing 25(OH)vitamin D levels and in-hospital mortality was observed (Table 2 and Figure 1 ). 

Perspective: Vitamin D 213 deficiency and COVID-19 severity -plausibly linked by latitude, ethnicity, impacts on 214 cytokines, ACE2 and thrombosis

Vitamin D: A magic bullet or a myth?

Vitamin D 218 Deficiency and Outcome of COVID-19 Patients

Evidence for 220 possible association of vitamin D status with cytokine storm and unregulated inflammation 221 in COVID-19 patients

Low serum 25-hydroxyvitamin D 224 (25[OH]D) levels in patients hospitalized with COVID-19 are associated with greater 225 disease severity

Vitamin D sufficiency